Key result
Metabolic disorders such as cachexia and sarcopenia frequently complicate heart failure and cancer, increasing morbidity and mortality while lacking established guideline-recommended therapies.
Why the study?
Heart failure and cancer frequently co-occur with metabolic disorders causing muscle wasting, yet few therapeutic options exist and guideline-recommended therapies for cachexia are lacking.
Sarcopenia and cachexia are critical, overlapping complications in both heart failure and cancer that significantly worsen prognosis and urgently require the development of targeted therapeutic strategies.
Answers are grounded in this paper and cite their sources.
Supports screening for cachexia and sarcopenia in HF and cancer; leaves open targeted therapies for prospective trials.
In an aging population, the number of patients affected by heart failure and cancer is constantly increasing and together these two conditions account for more than 50% of all deaths worldwide. Both diseases share similar risk factors including smoking, obesity, and hypertension. Presenting symptoms may also be similar, with patients frequently complaining of dyspnea, fatigue, and anorexia. Many affected patients, especially those with more advanced heart failure or cancer, suffer also from metabolic disorders. These can lead eventually to muscle wasting, sarcopenia, and cachexia. These complications are associated with increased morbidity, a poorer quality of life, a worse prognosis and indeed they represent an independent risk factor for the advancement of the underlying disease itself. Very few therapeutic options have been established to treat these co-morbidities. For sarcopenia the only validated treatment is resistance training. Moreover, there is currently no guideline recommended therapy for the treatment of cachexia. New treatment strategies are urgently needed to prevent and treat muscle and wasting disorders in patients with chronic diseases such as cancer and chronic heart failure.
No takes yet. Share an insight, caveat, or question.
Lena et al. (2018) conducted a review in Heart failure and cancer (cachexia and sarcopenia). Metabolic disorders such as cachexia and sarcopenia frequently complicate heart failure and cancer, increasing morbidity and mortality while lacking established guideline-recommended therapies.
Synapse has enriched 10 related papers. Consider them for comparative context: